Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 49Terminated 10Recruiting 5Unknown 3Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Colorectal Neoplasms 16Glioblastoma 8Ovarian Neoplasms 7Colonic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 6Pancreatic Neoplasms 5Rectal Neoplasms 4Carcinoma, Renal Cell 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Neoplasms 2Melanoma 2Liver Neoplasms 2Fallopian Tube Neoplasms 2Endometrial Neoplasms 2Central Nervous System Neoplasms 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Rectal Cancer Patients 1Prostatic Neoplasms 1Platinum-Refractory Fallopian Tube Carcinoma 1Peritoneal Neoplasms 1Optic Nerve Diseases 1

Interventions

Magnetic Resonance Spectroscopy 5Temozolomide 2Immunotherapy, Adoptive 2Aminolevulinic Acid 2thymoglobulin 1temsirolimus 1poly ICLC 1pembrolizumab 1pazopanib 1orludodstat 1keyhole-limpet hemocyanin 1gallium Ga 68 dotatate 1fludarabine phosphate 1fluciclovine F-18 1dexamethasone acetate 1dexamethasone 21-phosphate 1cixutumumab 1carbon-11 acetate 1cabazitaxel 1bicalutamide 1azeliragon 1auricularum 1atezolizumab 1abemaciclib 1Valproic Acid 1Trail Making Test 1Topotecan 1Thiotepa 1Tacrolimus 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Glioma × Bevacizumab × Clear all
NCT02754362 2020-01-13

A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma

NYU Langone Health

Phase 2 Withdrawn
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡